AMO viscoelastic gains FDA approval

Article

Healon D latex-free viscoelastic (AMO) has been granted premarket approval by the FDA. The clear dispersive ophthalmic viscosurgical device (OVD) is designed to be used during phacoemulsification, intraocular lens (IOL) implantation, keratoplasty and glaucoma filtration surgery.

Healon D latex-free viscoelastic (AMO) has been granted premarket approval by the FDA. The clear dispersive ophthalmic viscosurgical device (OVD) is designed to be used during phacoemulsification, intraocular lens (IOL) implantation, keratoplasty and glaucoma filtration surgery.

Healon D has low viscosity and low molecular weight, allowing it to provide lubrication for IOL insertion and to remain coating the cornea throughout surgery, thereby providing endothelial cell protection. Healon D will be available in dual-packs with either standard Healon, or with Healon GV, an existing AMO OVD, which has a high viscosity and high molecular weight.

The packs containing Healon D will be available before the end of the year.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.